Sponsors (8)
Introduced May 15, 2025 by Gary C. Peters · Last progress May 15, 2025
The bill strengthens identification, transparency, and coordination to secure essential drug supplies and improve preparedness, but it does so at the cost of new government and industry reporting requirements, taxpayer-funded actions, and increased risk of exposing sensitive commercial or security information that could cause short-term disruptions.
Patients (especially those with chronic conditions) are more likely to retain access to critical medicines because the bill creates an essential medicines list, federal inventory, and predictive analytics to identify vulnerabilities and anticipate shortages.
Hospitals and health systems get clearer, actionable guidance on priority drugs and domestic manufacturing capacity, improving procurement planning and preparedness for shortages.
Military and civilian preparedness is strengthened because the bill improves identification of medicines needed for CBRN responses, highlights Defense-purchased drugs with risky sourcing (e.g., China links), and enables targeted use of authorities to bolster domestic production.
Taxpayers will face new and ongoing costs because maintaining lists, inventories, analytics, reports, and interagency coordination requires federal funding and staff time.
Publishing supply-chain vulnerabilities and detailed sourcing information risks exposing sensitive commercial or security information that adversaries or competitors could exploit.
Manufacturers, registrants, and federal agencies will face increased administrative and compliance burdens (reporting, data collection, mapping, and analytics) that could divert staff and resources from other programs.
Based on analysis of 7 sections of legislative text.
Requires HHS to list essential drugs/APIs, assess and map their supply chains with DOD, and report regularly to Congress; DOD must report on China-sourced drugs every 180 days.
Requires HHS to maintain and update an "Essential Medicines List" of drugs and active pharmaceutical ingredients (APIs) that are critical for public health, military readiness, or vulnerable to shortage. It directs HHS (with DOD and other agencies) to assess risks, map and visualize U.S. supply chains for those medicines, use data analytics to find vulnerabilities, and report regularly to Congress. The Department of Defense must separately report every 180 days on drugs it bought that were sourced or manufactured in the People’s Republic of China. The law also authorizes secure interagency data sharing and requires cybersecurity protections for exchanged information.